Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

GamePlan4Care: Online Support for Family Caregivers

NCT04540198
View directory record Official record
Conditions
Dementia
Interventions
GamePlan4Care, Resources4Care
Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 22, 2026, 9:34 PM EDT
Withdrawn Not applicable Interventional

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCT02661347
View directory record Official record
Conditions
Schizophrenia, Schizophreniform, Schizoaffective Disorder, Psychosis Not Otherwise Specified (NOS)
Interventions
Risperidone, tDCS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 22, 2026, 9:34 PM EDT
Recruiting Not applicable Interventional

Analgesia-First Sedation in Trauma Patients

NCT05751863
View directory record Official record
Conditions
Mechanical Ventilation, Respiratory Failure
Interventions
Analgesia First Sedation Strategy for Mechanically Ventilated (MV) Trauma Subjects, Protocol Directed Sedation and Daily Sedation Interruption
Other
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 22, 2026, 9:34 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Encinitas, California • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

NCT05005845
View directory record Official record
Conditions
Cutaneous Neurofibroma, Neurofibromatosis 1
Interventions
NFX-179 gel, Vehicle gel
Drug
Lead sponsor
NFlection Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 22, 2026, 9:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Gene by Medication Interaction to the Acute Effects of Alcohol

NCT01343628
View directory record Official record
Conditions
Alcohol-induced Cue-craving, Alcohol Sensitivity
Interventions
Placebo Comparator, Active Comparator: Atomoxetine, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Charlottesville/ Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 22, 2026, 9:34 PM EDT
Withdrawn Phase 4 Interventional

Botulinum Toxin-A for Hidradenitis Suppurativa

NCT06237465
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hidradenitis Suppurativa \(HS\), Hidradenitis Suppurativa, Acne Inversa
Interventions
Normal saline, Botulinum toxin type A
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Guilford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 22, 2026, 9:34 PM EDT
Suspended Phase 3 Interventional

Investigational Study of Delayed Release Metformin

NCT04854512
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin DR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Drug
Lead sponsor
Anji Pharma
Industry
Eligibility
18 Years to 100 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Glendale, Arizona • Mesa, Arizona • Apple Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 22, 2026, 9:34 PM EDT
Terminated Phase 3 Interventional

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

NCT06431256
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
4 Years to 5 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

NCT01759056
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVX 470, Placebo
Drug
Lead sponsor
Avaxia Biologics, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional

Soy Formula Feedings in Healthy, Term Infants

NCT02456831
View directory record Official record
Conditions
Gastrointestinal Tolerance
Interventions
Experimental Infant Formula 1, Experimental Infant Formula 2, Experimental Infant Formula 3, Active Comparator: Control Infant Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
2 Weeks to 9 Weeks
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1994
U.S. locations
7
States / cities
Little Rock, Arkansas • Aurora, Illinois • Owensboro, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional

Prevention of Arthritis-Related Work Disability

NCT00000416
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Knee, Ankylosing Spondylitis
Interventions
Rehabilitation counseling
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 22, 2026, 9:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Health Equity and Rural Education (HERE!) Clinical Trial

NCT06460116
View directory record Official record
Conditions
Behavioral Symptoms, Community Health Workers, Social Determinants of Health, Educational Problems
Interventions
School-Based Community Health Worker (SB-CHW) intervention, Enhanced Usual Care (EUC) Methods
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
12 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Lozenges and Assisted Self-help for Smokeless Tobacco Cessation

NCT01341938
View directory record Official record
Conditions
Smokeless Tobacco Cessation
Interventions
Commit® nicotine lozenges (4 mg) & self-help materials, Commit® nicotine lozenges (4 mg) & phone counseling & self-help materials, Phone counseling & self-help materials
Drug · Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 22, 2026, 9:34 PM EDT
Recruiting Early Phase 1 Interventional

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

NCT06482853
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High Quality Protein for Assisting With Weight Loss

NCT03085511
View directory record Official record
Conditions
Obesity
Interventions
Egg breakfast (EB), Weight Loss Counseling, Weight Loss Diet, Cereal Breakfast (CB)
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional Results available

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

NCT01951339
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Disease
Interventions
Sitagliptin, Glimepiride, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

NCT00750139
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
NAFT-500, Placebo 2-weeks, Naftin 1%, Placebo 4-weeks
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of Safety and Efficacy of realSKIN® (Skin Xenotransplant) for Complete Closure of Severe Burn Wounds

NCT03695939
View directory record Official record
Conditions
Deep Full-thickness Burn Injury (Disorder)
Interventions
realSKIN (skin xenotransplant), Human Cadaver Allograft
Biological
Lead sponsor
XenoTherapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Augusta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

Lumbar Plexus vs Quadratus Lumborum Block in Post-operative Pain Following Total Hip Replacement

NCT03801265
View directory record Official record
Conditions
Hip Osteoarthritis
Interventions
Lumbar plexus block, Quadratus lumborum type 3 block, Ropivacaine injection
Procedure · Drug
Lead sponsor
Sharad Khetarpal
Other
Eligibility
18 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

Oral Sedation During Cervical Dilator Placement

NCT03202550
View directory record Official record
Conditions
Oral Sedation and Cervical Dilator Pain
Interventions
Oxycodone and Lorazepam (Active Comparator), Placebo Comparator
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

NCT00865761
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam 3 mg Extended Release Tablets, single dose, XANAX XR® 3 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

NCT03346070
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate, Rocuronium or Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 22, 2026, 9:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

NCT02106923
View directory record Official record
Conditions
Healthy
Interventions
1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR, 2 tablets 5 mg Empagliflozin/750 Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 22, 2026, 9:34 PM EDT